Do you face the challenge of recruiting and retaining rare disease patients for orphan drug clinical trials? Now, discover how you can boost participation, enhance outcomes and speed drug development in this competitive market.
This webinar includes tips to help quality, project management, clinical, and site personnel manage conflicts as well as a review of the applicable regulations and reporting requirements.
In this webinar, the challenge of the prompt reporting of a low or high number of SUSARs to Investigators in global and large-scale clinical trials will be addressed.
In this webinar, Dr. Arun Sanyal will discuss risk factors for nonalcoholic fatty liver disease (NAFLD) disease progression and the implications in clinical development.
In this webinar we will first provide a high level review of the medical underpinnings of the diabetic heart particularly as it relates to heart failure. Understanding the structural, metabolic and functional associations of T2D will help us to better understand how some molecular classes could lead to benefits in CV outcomes while others may be detrimental.
As biosimilars to treat rheumatic diseases begin get approval from the FDA, biosimilar development remains a hot topic in drug development. Sponsors estimate a 35% growth of biosimilars in their development pipelines by 2020, but face a wide variety of regional and global markets along with shifting guidelines and recommendations, stressing the need to understand this rapidly changing landscape. What is the real potential for clinical and health-economic benefits offered by these agents?
During this webinar, we will examine multiple strategies that make the procedure of finding a better electronic data capture solution less frustrating and more beneficial to your organization.
Chesapeake IRB and CRF Health team up for a collaborative webinar to discuss informed consent oversight and visibility and why Top Pharma is turning to Electronic Informed Consent (eConsent) to exceed in these areas.
The burden of ineffective and inefficient body maps creates risks that can impact data quality. We knew we could come up with something much better - for all stakeholders.
A paradigm shift is needed in order to eliminate the three evil "e's" — email, Excel, and e-meetings — long associated with starting clinical trials, with the potential to ultimately reduce timelines and improve data quality. The webinar with focus on addressing the inefficiencies associated with the three evil "e's".
|
|
|
|
|
|
|
|
|